F10 and atrial fibrillation: In contrast, rivaroxaban was prescribed at a low dose in 21.7% of total patients in the real-world study, similar to the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism (ROCKET-AF)trial [21].